Canadian pharmaceutical companies have been extraordinarily successful in developing a safe and effective method of treating mental health problems in the area of mental health and well-being, not only in business and research, but also in developing psychedelics for evidence-based treatment of problems such as anxiety, PTSD, depression, and so on.

Here is a list of some of the top psychedelic pharmaceutical companies helping Canada to be one of the top players in the world.

• Bright Minds

Over the years, not only have there been first-generation psychedelic researches that were focused on mental health, but they have also been effective to an extent. But one of the unavoidable drawbacks of the first-generation psychedelics is that they were toxic and used to have long-lasting hallucinogenic experiences.

Bright Minds is trying to fix these issues and limitations of first-generation psychedelics by creating next-generation serotonergic drugs to treat neuropsychiatry disorders, epilepsy, and pain.

• Numinous Wellness

Numinous Wellness is a mental health company with possession of dealer’s license from Health Canada for importing, exporting, possessing, testing, and distributing various types of drugs like psilocin, DMT, mescaline, LSD, MDMA, Ketamine, etc.

Numinous Wellness also holds a license from Health Canada to test cannabis. Their lab, Numinous Biosciences, is Health Canada licensed for research of psychedelic substance and therapy.

Numinous plans to expand their research lab space by the end of the year, where at least 7,500 square feet is expected to be enlarged adjacent to the existing lab.

• Diamond Therapeutics

Diamond Therapeutics started by developing psilocybin-based therapies for neuropsychiatric conditions. Based in Toronto, Canada, Diamond Therapeutics is a psychedelic pharmaceutical company that believes psychedelic-based products are applicable in a wide range of aspects without perpetual side effects.

Funded studies of drugs from Diamond Therapeutics conclude that hallucinogenic effects are not necessary to have a potential therapeutic effect.

They have recently received approval to test low and healthy psilocybin doses in suitable individuals to determine the effects. This clinical trial which is said to have around 80 participants for the trial, will also test the safety of psilocybin doses.

• Revive Therapeutics

Revive Therapeutics’ cannabinoid pharmaceutical portfolio is developed to treat rare inflammatory diseases and therapeutics for rare disorders. They have developed CBD to treat auto-immune hepatitis (liver disease), ischemia and reperfusion injury that occurs from organ transplantation. Because of this, they also hold the FDA orphan drug status.

Revive Therapeutics is working on psychedelic based product pipelines, with development and clinical studies aiming to bring out the potential therapeutic value of psilocybin in various aspects

Conclusion

As many Canadian pharmaceutical companies have started their modern methods of mental health treatment, it is not only helping people to have treatment without side effects but also helping the pharmaceutical sectors of other countries to get inspired and start their own psychedelic researches.